Sorry, you need to enable JavaScript to visit this website.
跳转到主要内容


甲磺酸仑伐替尼

甲磺酸仑伐替尼
CAS Number: 857890-39-2

甲磺酸仑伐替尼

治疗类别
抗癌/抗肿瘤
API技术
合成
剂型
口服固体制剂
瑞迪博士研发状态
可得到
注册备案情况
USA
创新品牌(美国)
LENVIMA

Mechanism of Action

Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate 2α (FRS2α) phosphorylation. The combination of lenvatinib and everolimus showed increased antiangiogenic and antitumor activity as demonstrated by decreases in human endothelial cell proliferation, tube formation, and VEGF signaling in vitro, and by decreases in tumor volume in mouse xenograft models of human renal cell cancer that were greater than those with either drug alone.

Indication

LENVIMA is a kinase inhibitor that is indicated:

  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.
  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 甲磺酸仑伐替尼 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

联系我们

请填写以下表格,我们会尽快与您联系

给我们发电子邮件: api@drreddys.com |   +91 40 49002253

免责声明

受有效专利保护的产品不得在销售此类产品构成专利侵权的国家/地区销售。可获得性可能仅限于某些市场或国家/地区。有关可获得性和产品适用性的更多信息,请 我们联系 .

所有产品信息,包括有关活性药物成分(API)、适应症和可能的作用机制的信息均基于公开的产品标签。

给我们发电子邮件: api@drreddys.com | +91 40 49002253